Pfizer’s Xeljanz goes head-to-head with AbbVie’s Humira in RA study
The firm has announced top-line results from ORAL Strategy, a Phase 3B/4 study of Xeljanz (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid